VANCOUVER, BC, May 20, 2024
/PRNewswire/ - Today, Terragnosis Inc., a Canadian drug
development company, announced IBEX011, the first GMP extract of
Tabernanthe iboga available for use in ibogaine clinics and
academic research. IBEX011 also marks the first time that an
ibogaine product is compliant with the Nagoya protocol, a UN treaty which ensures
equitable benefits for traditional knowledge holders from the Bwiti
tradition in Gabon.
Iboga root bark has been used for millennia for traditional
healing and initiation rites, and more recently in international
clinics that treat drug addiction and neurological conditions,
including traumatic brain injury. Ambio Life Sciences, the
world's largest medical ibogaine facility, treating over 50
patients a month, will be the first clinic to use Terragnosis'
iboga extract with patients.
Jonathan Dickinson, the CEO of
both Terragnosis and Ambio, said, "This marks a common-sense shift
in how we think about the production of psychedelic medicine. We've
gone back to the source to build relationships with the most
experienced practitioners. Our goal is to offer the product with
the most potent healing properties."
While most ibogaine in use today is produced semi-synthetically
using chemicals extracted from alternative plant sources, IBEX011
contains all of the naturally occurring alkaloids found in T.
iboga root bark. This new extract is at least 30% stronger by
weight than single molecule ibogaine products.
"What we've seen so far has surprised us," said Ambio co-founder
and Chief Operations Officer Trevor
Millar. "We're excited to demonstrate what a standardized
botanical like this will mean for the healing and optimization of
our patients."
Terragnosis' iboga is sourced from the A2E Association in
Ebyeng, a Fang community in northeastern Gabon. The story of Aloïse Amougou, whose
visionary insight to begin planting iboga came after his own
initiation 20 years ago, was the subject of a 2023 feature story in
National Geographic.
The architecture of Gabon's
Nagoya strategy was developed and
implemented by Blessings of the Forest (BoTF), a non-profit
dedicated to the preservation and development of Gabonese cultural
and natural heritage. A2E is the first of 20 farms financed by
BoTF, and after a decade of work the project promises to set a new
precedent for access and benefits sharing in psychedelic production
and the pharmaceutic industry.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ibex011-the-first-nagoya-compliant-gmp-iboga-extract-is-now-available-for-clinical-use-and-academic-research-302149522.html
SOURCE Terragnosis Inc.